http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Ha Phuong Linh ),( Hoang Van Tiep ),( Dinh Cong Dang ),( Nguyen Khac Hung Manh ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Chronic hepatitis C is a major infectious disease which is mainly cause of morbidity worldwide in patients with liver disease, and liver transplantation. Raised ferritin levels play an important role of intervening the process which is associated with hepatic injury. Screening with non-invasive strategies can detect the disease at early stage and intervention could be initiated. To determine correlation between serum ferritin levels and liver stiffness values in patients of chronic hepatitis C. Methods: A cross-sectional study was conducted at 103 Cam Khe Clinic from May 2019 to April 2020. 93 patients with chronic hepatitis C fulfilling inclusion criteria were included in this study. Liver fibrosis stages was appreciated using transient hepatic elastography by Fibroscan, the activities of serum liver function biomarker enzymes and serum ferritin levels were determined by automated analyser. Results: The average age of patients was 48 years, with men accounted for 78% of the total. The mean serum ferritin value was 148.19 ng/ml, liver stiffness measurements range from 12.5 to 75.5 kPa, with a median value of 17.39 ± 15.98 kPa. Significantly elevated levels of serum ferritin (P<0.001), were detected in patients with severe fibrosis compared to mild fibrosis. Concentration of serum ferritin was increased with the evolution of fibrosis in all stages from F0 to F4 and this increase was significant (P<0.01) in cirrhotic patients (F4). There was a positive correlation between serum level of ferritin and progression of fibrosis (0.979391) (r = 0.976). Conclusions: There is significant correlation between serum ferritin and liver stiffness. Serum ferritin concentration may be used as liver fibrosis biomarkers.
( Ha Phuong Linh ),( Hoang Van Tiep ),( Dinh Cong Dang ),( Nguyen Khac Hung Manh ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Background: Tenofovir disoproxil fumarate (TDF) is one of the first optimal choices to be used in the treatment of chronic hepatitis B. FibroScan is non-invasive methods to assess liver fibrosis. Aims: To evaluate the therapeutic effect of TDF on fibrosis via FibroScan after treatment. Methods: This study was conducted in 63 chronic hepatitis B patients who had the indication of antiviral therapy at 103 Cam Khe Clinic from March 2019 to March 2020. All patients with chronic hepatitis B treated with TDF during 6 months. Liver fibrosis stages was appreciated using transient hepatic elastography by Fibroscan before and after 6 months treatment. Results: The average age of patients was 46 years, with men accounted for 69% of the total. After treatment, normalization of ALT 71.26%, viral response of 90.23%, HBV DNA below the detection level was 66.3%. Liver fibrosis evaluated by FibroScan before and after 6 months treatment were 7.15 ± 1.56 kPa, and 3.58 ± 1.19 kPa eveluated by FibroScan. Conclusions: TDF was effective for patients after treatment on liver fibrosis assessed by FibroScan in chronic hepatitis B patients.